In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CeNeS Pharmaceuticals PLC

Division of Paion AG

Latest From CeNeS Pharmaceuticals PLC

Appointments: Sanofi, Recipharm, Axovant, e-Therapeutics & Diplomat

This week’s roundup includes the appointment of Sanofi Genzyme’s executive vice president and various high-level appointments by companies including Recipharm, e-Therapeutics, Diplomat Pharmacy and Axovant.

Appointments BioPharmaceutical

Stockwatch: Pain in the middle eight

In popular music parlance, the middle eight is the part of a song that is not a chorus or a verse. In America, it's called the bridge, although it can also be thought of as either the padding or less memorable parts of a music track. If life science companies were to be classified as either chorus, verse or middle eight companies, profitable biotechnology companies like Gilead Sciences and Celgene (which we own), that have attained the size that means they may never be acquired, would be the verses, while the chorus would include those companies like Regeneron Pharmaceuticals (which we own) and Alexion Pharmaceuticals that have easily surpassed profitability, but are not yet so big that they could never be acquired.

Neurology Companies

Phase I for Acorda's new mechanism of action in heart failure justifies more studies

Phase I data are sufficient to justify another human clinical trial in the treatment of heart failure with Acorda Therapeutics' glial growth factor 2 (GGF2), which offers a new mechanism of action that may improve heart function through direct repair of cardiac muscle.

Cardiovascular Cancer

Stockwatch: They shoot biotech horses don't they?

This year, as well as last, the death of two horses at the recent UK Grand National race has led to a considerable amount of consternation amongst the horseracing, and even the general community. Interestingly, there are striking similarities between what has led to the death of so many UK biotechnology companies, and the changes that have led to the deaths at the Grand National.

See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Core Group PLC
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Paion AG
  • Senior Management
  • Neil Clark, CEO
    Gavin Kilpatrick, PhD, CSO
  • Contact Info
  • CeNeS Pharmaceuticals PLC
    Phone: (44) 1223 266 466
    Compass House, Vision Park
    Chivers Way
    Histon, CB24 9ZR